Candida in the ICU, risk management and patient safety

Endogenous candidiasis remains an underrecognized yet clinically relevant complication
in non-neutropenic critically ill patients. This study examines Candida spp. infections in
the intensive care unit (ICU) within a patient-safety and risk-management framework,
focusing on the identification of patients at highest risk and the development of an early
diagnostic and therapeutic strategy. The target population comprises long-stay ICU patients
requiring prolonged mechanical ventilation who develop multiple organ dysfunction
syndrome (MODS) associated with immunoparalysis, typically reflected by a Sequential
Organ Failure Assessment (SOFA) score ≥ 5. In this population, Candida spp. colonization
may evolve into multifocal candidiasis and subsequently invasive or disseminated disease.
Notably, candidemia often represents a late manifestation and therefore lacks sensitivity
as an early diagnostic marker. Drawing on a series of clinical investigations conducted
from 1978 to the early 2000s, the authors developed a standardized diagnostic–therapeutic
algorithm based on systematic surveillance cultures, identification of multifocal Candida
spp. colonization, and early initiation of antifungal therapy. Implementation of this strategy,
together with progressive individualization of antifungal treatment, was associated with a
marked reduction in attributable mortality related to candidiasis in ICU patients. These
findings support the concept of Candida spp. infection as a sentinel indicator of systemic
immune dysfunction and physiological fragility in critical illness. Integrating risk-based
surveillance with early targeted therapy may substantially improve outcomes and reinforce
patient-safety strategies in the ICU.